Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Dulaglutide vs Mazdutide

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Dulaglutide has stronger documented evidence (FDA-Approved) than Mazdutide (Phase 3 (China)) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Dulaglutide is the safer pick. Mazdutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Dulaglutide

FDA-Approved

Mazdutide

Phase 3 (China)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Dulaglutide Mazdutide
Class GLP-1 receptor agonist GLP-1/glucagon dual agonist
Drug class Metabolic & Weight Metabolic & Weight
Mechanism GLP-1 receptor agonist fused to human IgG4 Fc Oxyntomodulin analog; activates GLP-1 and glucagon receptors
Route SC injection SC injection
Half-life ~5 days Long-acting weekly
Dosage (research) 0.75 mg SC weekly (Trulicity label starting dose, escalate stepwise to 1.5, 3.0, then label max 4.5 mg weekly for additional glycemic control per AWARD trials) 3-9 mg SC weekly
Evidence tier FDA-Approved Phase 3 (China)
Research depth 311 indexed (PubMed 190 · CT 64 · EPMC 57) 126 indexed (PubMed 48 · CT 45 · EPMC 33)
Availability Prescription Investigational
Reported risks Nausea; diarrhea; pancreatitis risk; thyroid C-cell tumor warning GI effects; no Western approval

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Dulaglutide or Mazdutide?

Dulaglutide has stronger documented evidence (FDA-Approved) than Mazdutide (Phase 3 (China)) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Dulaglutide is the safer pick. Mazdutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Dulaglutide and Mazdutide?

Dulaglutide is classed as GLP-1 receptor agonist; Mazdutide is classed as GLP-1/glucagon dual agonist. Reported mechanism: Dulaglutide, GLP-1 receptor agonist fused to human IgG4 Fc; Mazdutide, Oxyntomodulin analog; activates GLP-1 and glucagon receptors. Reported half-life: Dulaglutide, ~5 days; Mazdutide, Long-acting weekly. Routes in published studies: Dulaglutide, SC injection; Mazdutide, SC injection.

Which has stronger evidence, Dulaglutide or Mazdutide?

Dulaglutide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Dulaglutide is graded FDA-Approved, with 41 cited sources on its reference page and 311 indexed studies. Mazdutide is graded Phase 3 (China), with 23 cited sources on its reference page and 126 indexed studies.

Which is more accessible, Dulaglutide or Mazdutide?

Dulaglutide is FDA-approved and Mazdutide is not. Catalog status: Dulaglutide, Prescription; Mazdutide, Investigational.

Are Dulaglutide and Mazdutide ever combined?

Dulaglutide and Mazdutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…